A Phase 3 interventional study of Probiotic (Inersan) and Placebo in Chronic Periodontitis, sponsored by CD Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-07-27.
Sponsored by CD Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Chronic Periodontitis with a site in India — 2 open to participants now, 3 under way, none of them phase 3. Chronic Periodontitis · India.
Among the 53 studies in Chronic Periodontitis with a site in India, this one is the 30th largest by enrollment of the 46 interventional ones that give a count, is one of 7 that started in 2014, is one of 8 in phase 3, and was the 11th registered.
377 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.
Browse Chronic Periodontitis studies →2 of the 53 studies in Chronic Periodontitis with a site in India are open now. Recruiting first, the newest first:
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30–50
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30–50 · Healthy volunteers
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 17 · Phase 4 6
First in 2011; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 46 across 307 interventional studies indexed under Chronic Periodontitis.
Median enrollment 53 across the 46 interventional studies, 90 across the 7 observational. Of the 43 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 53 have an industry lead sponsor. The 10 most frequent:
CD Pharma India Pvt. Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
CD Pharma India Pvt. Ltd. has 3 studies filed under Chronic Periodontitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 53 studies in Chronic Periodontitis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Periodontal disease is an infectious disease resulting in inflammation within supporting tissues of the teeth, progressive attachment loss, and bone loss. Epidemiological studies reveal that about 10% of the adult population suffer from severe periodontitis.It comprises of two distinct but interconnected etiologic components: the periodontopathic bacteria adjacent to the periodontal tissues, and the host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products. In the arena of periodontics, the probiotics pose a great potential of plaque modification, halitosis management, altering anaerobic bacteria colonization, improvement of pocket depth, and clinical attachment gain.
Aim of the study is to analyze the beneficial effect of probiotic lozenges as an adjunct to Scaling and Root Planing, on clinical and biochemical parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
Drug: Probiotic (Inersan)
Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Drug: Placebo
Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Improvement in Periodontal Clinical indices
Improvement in periodontal clinical indices, namely, Gingival Index (GI), Plaque Index (PI), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).
Time frame: 6 weeks
Improvement in biochemical indices
Changes in level of inflammatory markers namely PGE2, IL-1beta, TNF-alpha, receptor activator of nuclear factor kappa B ligand (RANKL), Osteoprotegerin (OPG), MMP-9 and MMP-13 in saliva sample
Time frame: 6 weeks
The record gives a start of Jul 2014, a primary completion of Jan 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
CD Pharma India Pvt. Ltd.